Key Market Indicator:
F&G: 40
25.233,35 NASDAQ · 48.573,00 DOW · 6.841,40 S&P · 4.299,43 Gold · 61,01 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
US45337C1027
Filter zurücksetzen
© BusinessWire
08.01.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte Corporation (Nasdaq: INCY) announced today that it granted equity inducement awards to Mohamed Issa, the Company’s new Executive Vice President, Head of U.S. Oncology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement ma...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conference
Article
News Preview
Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mis...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
Article
News Preview
Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refra...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
07.12.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
Article
News Preview
Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.12.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved b...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
Article
News Preview
Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solv...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
Article
News Preview
Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers,” said Pablo J. Ca...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
Article
News Preview
Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conference
Article
News Preview
Incyte (Nasdaq: INCY) announced today that it will present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an aggregate of 15,812 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incenti...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
Article
News Preview
Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be we...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Article
News Preview
Incyte (Nasdaq:INCY) today reports 2024 third quarter financial results, and provides a status update on the Company’s clinical development portfolio. "In the third quarter of 2024, we delivered significant achievements, including strong revenue growth for both Jakafi® (ruxolitinib) and Opzelura® (ruxolitinib) cream, and the advancement of our cl...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
Article
News Preview
Incyte announced today that for the seventh consecutive year, it has been named a top five biotech and pharma employer based on Science magazine’s annual survey. This year, Incyte was ranked third and specifically recognized for its commitment to employee respect, social responsibility and employee loyalty. In addition to this recognition, earlie...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
Article
News Preview
Incyte (Nasdaq:INCY) announced today the expansion of its Moments of Clarity program, an educational initiative highlighting stories of people living with mild to moderate atopic dermatitis (AD) and their paths to finding relief. Building on last year’s program launch in partnership with Mandy Moore, the Moments of Clarity program will now feature...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Report Third Quarter Financial Results
Article
News Preview
Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: O...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 22,107 shares of the Company’s common stock to 26 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of October 1, 2024, and were approved b...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte (Nasdaq:INCY) announced that today it granted an equity inducement award to Lee Heeson, the Company’s new Executive Vice President, Incyte International, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The award was approved by the compensation committee of the Company’s Board of Directors as an inducement material to Mr. He...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
Article
News Preview
Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 held September 25-28 in Amsterdam. “We’re excited to present five late-breaking oral presentations at this year...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
Article
News Preview
Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) with new, updated data shared during the Company’s investor...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
Article
News Preview
Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-303/InterAACT2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy (carboplatin–paclitaxel) for the treatment of adults with inoperable locally recurrent or metastatic squamo...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 11,497 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of September 3, 2024, and were approved...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
Article
News Preview
Incyte (Nasdaq: INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually. "The data at ESMO underscore the progress across our oncology portfolio and the potential to impact patients whe...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
Article
News Preview
Incyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients w...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Article
News Preview
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte to Present at Upcoming Investor Conferences
Article
News Preview
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT) Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT) Cantor Global Healthca...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 14.12.2025, Calendar Week 50, 348th day of the year, 17 days remaining until EoY.